When making treatment regimens for these comorbidities, drugs that increase renal UA excretion are recommended, such as calcium channel inhibitors or losartan for hypertension, glitazones and biguanides for diabetes (sodium-glucose cotransporter 2 inhibitors, SGLT-2), and fenofibrate or atorvastatin for dyslipidemia (56, 90–92). This evidence concerns the gene SLC5A2 and Hypertension.